Ketamine for depression: all studies (page 33)

Astroglia and depression: A Gliocentric perspective from rodent models to therapeutic insights.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 27, 2026 Rhea Subba, Surendar Ellappan, Sugato Banerjee et al.

Major depressive disorder (MDD) is a debilitating neuropsychiatric condition that affects individuals worldwide. While neuronal deficits have long been recognized in depression pathogenesis, astroglia are increasingly gaining attention. Astroglia are essential for maintaining brain homeostasis, and regulate neurotransmission, neuroinflammation, and metabolic processes that are disrupted in MDD....

DOI: 10.1016/j.pnpbp.2026.111627 Full text Depression Ketamine Major depressive disorder Antidepressants +4

Serial ketamine infusions not effective as adjunctive care for depression

The Brown University Psychopharmacology Update January 24, 2026

Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatient treatment for depression, a randomized trial has found. Patients receiving ketamine also showed no improvement relative to those receiving midazolam on measures of cognition and quality of life. Study results were published online Oct. 22, 2025 in...

DOI: 10.1002/pu.31401 Ketamine Depression economics Placebo Midazolam +6

Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.

BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations

Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...

DOI: 10.1192/bjo.2025.10950 Full text Treatment-resistant depression Esketamine Long-term effectiveness Maintenance therapy +1

Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.

Translational Psychiatry January 23, 2026 Stevan Nikolin, Clara Massaneda-Tuneu, Louise Brettell et al. 1 citation

Comparing treatments for severe and medication-resistant depression is essential for guiding clinical decision-making. In this meta-analysis, we investigate the efficacy of electroconvulsive therapy (ECT) compared to ketamine for the treatment of major depressive disorder (MDD) and address the discrepant results of prior meta-analyses. We systematically searched PubMED (MEDLINE), Embase, and...

DOI: 10.1038/s41398-026-03806-z Full text

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

DOI: 10.1016/j.jad.2026.121230 Full text Anxiety Treatment-resistant depression Iv ketamine Real-world evidence +1

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.

Journal of Neuroinflammation January 22, 2026 Ang Liu, Xiao-Qi Zhang, Jia-Xin Guo et al.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and depression frequently co-occur, yet the biological basis of this comorbidity and effective therapeutic strategies remain poorly defined. METHODS: We established a rat model of COPD-depression comorbidity through sequential cigarette-smoke exposure and chronic unpredictable mild stress. Pulmonary function, depression-like behaviors,...

DOI: 10.1186/s12974-026-03699-1 Full text Depression Esketamine Animals Rats, sprague-dawley +8

Progress, potential and pitfalls of ketamine as a treatment for depression

Expert Opinion on Pharmacotherapy January 22, 2026 Diana Orsini, Sara Di Luch, Gabrielle F. M. Lovell et al.

Evidence supporting the use of intravenous ketamine and intranasal esketamine for depression has dramatically increased with a large number of clinical trials and real-world effectiveness studies supporting antidepressant effects. Larger studies have provided reassuring data supporting an adequate safety profile, including safety data with long-term treatment. Alternative routes of...

DOI: 10.1080/14656566.2026.2637587 Ketamine Treatment-resistant depression Antidepressant Clinical trial +4

Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study.

Indian Journal of Psychological Medicine January 22, 2026 Zaid Ahmad Wani, Rajnish Raj, Shabir Ahmad Dar et al.

Depression is a significant global health issue, often accompanied by suicidality, which requires urgent and effective interventions. Oral ketamine is emerging as a potential rapid-acting treatment, but data on its efficacy and tolerability remain limited, particularly in the Indian context. Thus, this retrospective study was conducted to assess the response to oral ketamine in patients with...

DOI: 10.1177/02537176251415001 Full text Depression Oral ketamine Rapid-acting antidepressant Sociocultural factors +1

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

DOI: 10.1186/s12991-025-00626-1 Full text Esketamine Treatment-resistant depression Antidepressant therapies Gcc mental health +2

Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.

Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation

Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...

DOI: 10.1016/j.jad.2026.121208 Full text Esketamine Mdd Treatment-resistant depression Intranasal racemic ketamine +1

Research